Back to results
US 2026/0308622 A1Published application
Lentiviral delivery of anti-cd20 chimeric antigen receptors
OwnerChristopher Nicolai, Weiliang Tang +7inventors
InventorsChristopher Nicolai, Weiliang Tang, Byoung Ryu, Ryan Larson, Jim Qin, Rebecca Jane Gottschalk, Wai-hang Leung, Lisa Yun Park, Maura Parker
Life of this patent
Estimating the term…
Abstract
Provided herein are particles comprising polynucleotide constructs for generating cells expressing anti-CD20 chimeric antigen receptor, as well as vectors, such as lentiviral vectors, comprising same, cells comprising same, and methods of using same.
Claims44
A lentiviral particle, comprising:
- a polynucleotide encoding a chimeric antigen receptor (CAR) that specifically binds cluster of differentiation-20 (CD20),
- wherein the CAR comprises a VL or VH sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:
- 176 or 179;
- and
- wherein the lentiviral particle comprises any of the following:
- a heterologous viral glycoprotein (G protein),
- a surface displayed polypeptide selected from:
- an anti-CD3 antibody or antigen-binding fragment, a CD28 ligand, or a 4-1BB ligand, or
- a fusion molecule comprising:
- a CD58 extracellular domain, or a functional fragment thereof, a CD80 or CD86 extracellular domain, or a functional fragment thereof, and an anti-CD3 antibody or antigen-binding fragment thereof.
7 more elements
A method, comprising administering the lentiviral particle of any one of the previous claims to a subject.
Dependencies are inferred from the claim text.